Intranasal delivery of nanoparticle-based vaccine increases protection against S. pneumoniae

Brittney Mott, Sanjay Thamake, Jamboor Vishwanatha, Harlan P. Jones

Research output: Contribution to journalArticlepeer-review

3 Scopus citations


Nanoparticle (NP) technologies are becoming commonplace in the development of vaccine delivery systems to protect against various diseases. The current study determined the efficacy of intranasal delivery of a 234 ± 87.5 nm poly lactic-co-glycolic acid nanoparticle vaccine construct in establishing protection against experimental respiratory pneumococcal infection. Nanoparticles encapsulating heat-killed Streptococcus pneumoniae (NP-HKSP) were retained in the lungs 11 days following nasal administration compared to empty NP. Immunization with NP-HKSP produced significant resistance against S. pneumoniae infection compared to administration of HKSP alone. Increased protection correlated with a significant increase in antigen-specific Th1-associated IFN-γ cytokine response by pulmonary lymphocytes. This study establishes the efficacy of NP-based technology as a non-invasive and targeted approach for nasal-pulmonary immunization against pulmonary infections.

Original languageEnglish
Article number1646
JournalJournal of Nanoparticle Research
Issue number5
StatePublished - May 2013


  • Immunity
  • Nanoparticle
  • Respiratory
  • Streptococcus pneumoniae
  • Vaccine


Dive into the research topics of 'Intranasal delivery of nanoparticle-based vaccine increases protection against S. pneumoniae'. Together they form a unique fingerprint.

Cite this